Governance 2020-2024

FHU CARE governance for 2020-2024 is based on a Management Committee, an Executive Committee and an external Scientific Advisory Board

The Management Committee is composed of:

The Management Committee is composed of:

• The coordinator : Xavier Mariette
• The WP leaders :WP1 Laurence Zitvogel, WP2 Raphaèle Seror, WP3 Aurélien Marabelle (also vice-coordinator of the project), WP4 Olivier Lambotte (also vice-coordinator of the project)
• 2 Clinicians, one representing autoimmunity/inflammation: Franck Carbonnel, one representing cancer: Benjamin Besse
• 3 Researchers, one representing autoimmunity/inflammation: Gaëtane Nocturne, one representing cancer: Nathalie Chaput-Gras, one representing microbiome, Patricia Lepage
• 6 Representatives, one from Greater Paris University Hospitals – AP-HP, INSERM, Université Paris-Saclay, IGR, CEA, INRAe.

The Management Committee is responsible of:

• Strategic, financial and managerial responsibilities
• Adoption of strategic decisions
• Approval of the annual workplan presented by the Executive Committee and supervision of its implementation
• Approval of the annual reports and the evaluation at the end of its mandate
• Decision about intellectual property (IPRs) of discoveries made by the consortium

The Executive Committee is composed of:

• The coordinator: Xavier Mariette
• The 2 vice-coordinators, one for Autoimmunity / Inflammation: Olivier Lambotte, Greater Paris University Hospitals – AP-HP, one for Cancer: Aurélien Marabelle, Institut Gustave Roussy
• 4 Tasks leaders
• The Head of Clinic provided by the University Paris Saclay
• The project manager provided by Greater Paris University Hospitals – AP-HP

And its main missions are:

• Elaboration and implementation of the annual workplan approved by the Management Committee;
• Monitoring of FHU indicators;
• Annual reporting to the funding organizations.

The External Scientific Advisory Board:

• Pr Antony Rosen from J Hopkins, Baltimore, a highly recognized AID/cancer relations expert
• Pr Len Calabrese from Cleveland clinic, an immune-rheumatologist expert in IrAEs of ICI
• Pr François Ghiringhelli from Dijon University, a famous cancer specialist
• Two Representatives of the French patients associations, one for AID (AFPRIC, ANDAR or AFGS) and one for cancer (Ligue contre le cancer)
• Three Representatives of the 3 pharmaceutical industries supporting the project, 2 of them located at the site of Université Paris-Saclay (Sanofi and Servier), the 3rd one being BMS.